BNP Paribas Financial Markets
TLX

BNP Paribas Financial Markets’s Telix Pharmaceuticals TLX Stock Holding History

BNP Paribas Financial Markets’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Buy
12,000
+10,500
+700% +$80K ﹤0.01% 4303
2025
Q4 		$11.2K Buy
+1,500
New +$14.4K ﹤0.01% 5135

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

BNP Paribas Financial Markets's TLX Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Telix Pharmaceuticals (TLX) stake by 700% in Q1 2026, buying an estimated $80K and bringing the position to 12,000 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #4303.

BNP Paribas Financial Markets first reported a position in TLX in Q4 2025 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • BNP Paribas Financial Markets held 12,000 shares of Telix Pharmaceuticals worth $115K as of Q1 2026.
  • BNP Paribas Financial Markets bought 10,500 Telix Pharmaceuticals shares in Q1 2026, an estimated $80K.
  • Telix Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4303 holding.
  • BNP Paribas Financial Markets first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.